Respiratory infection treating agent

Patent metadata

Field	Value
Publication number	US-2021052572-A1
Application number	US-202017090218-A
Country	US
Kind code	A1
Filing date	Nov 5, 2020
Priority date	Mar 13, 2015
Publication date	Feb 25, 2021
Grant date	—

Abstract

[Solution] A respiratory infection treating agent containing, as an active ingredient, 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquin oline-3-carboxylic acid or a pharmaceutically acceptable salt thereof.

First claim

1 - 13 . (canceled)

14 . A method of treating a respiratory infection comprising, administering 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat the respiratory infection to a subject in need thereof,
wherein the subject is human and wherein 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is administered in an amount of 10 mg to 250 mg per day.

15 . A method of treating an infection which is one or more infections selected from the group consisting of pharyngitis, laryngitis, tonsillitis, acute bronchitis, pneumonia, secondary infections of chronic respiratory diseases, sinusitis, and tympanitis, and in which pathogenic bacteria are Streptococcus pneumoniae , the method comprising, administering 7-[(3S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof in an amount effective to treat the respiratory infection to a subject in need thereof,
wherein the subject is human and wherein 7-[(3 S,4S)-3-{(cyclopropylamino)methyl}-4-fluoropyrrolidine-1-yl]-6-fluoro-1-(2-fluoroethyl)-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a pharmaceutically acceptable salt thereof is administered in an amount of 10 mg to 250 mg per day.

Assignees

• Kyorin Seiyaku Kk

Inventors

• Kume Kota
• Yoshida Hisao
• Ando Hirotaka
• Tanaka Yuta

Classifications

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title

• A61P31/04

  Antibacterial agents · CPC title

• A61P11/04

  for throat disorders · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K31/4709 Primary

  Non-condensed quinolines and containing further heterocyclic rings · CPC title